Assessing the cost-effectiveness of interventions linked to needle and syringe programmes for injecting drug users: An economic modelling report Authors

[1]  G. Dore,et al.  Treatment for hepatitis C virus infection among current injection drug users in Australia. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  M. Hudgens,et al.  Subtype-specific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand. , 2002, American journal of epidemiology.

[3]  R. Brettle,et al.  Geographical variation in disease progression in HIV-1 seroconverted injecting drug users in Europe? , 1999, International journal of epidemiology.

[4]  J. Kaldor,et al.  Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies , 2006, Journal of viral hepatitis.

[5]  B. Edlin,et al.  Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  M. Gossop,et al.  Economic analysis of costs and consequences of the treatment of drug misuse: 2-year outcome data from the National Treatment Outcome Research Study (NTORS). , 2004, Addiction.

[7]  Christopher D Pilcher,et al.  Brief but efficient: acute HIV infection and the sexual transmission of HIV. , 2004, The Journal of infectious diseases.

[8]  S. Currie,et al.  A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. , 2008, Drug and alcohol dependence.

[9]  Peter Vickerman,et al.  Model Projections on the Required Coverage of Syringe Distribution to Prevent HIV Epidemics Among Injecting Drug Users , 2006, Journal of acquired immune deficiency syndromes.

[10]  S. Vermund,et al.  Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. , 2001, AIDS research and human retroviruses.

[11]  G. Foster,et al.  Community‐based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use , 2009, Alimentary pharmacology & therapeutics.

[12]  J. Kaldor,et al.  High incidence of hepatitis C virus reinfection within a cohort of injecting drug users , 2007, Journal of viral hepatitis.

[13]  O. Dalgard.  Follow-up studies of treatment for hepatitis C virus infection among injection drug users. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  J. Hippisley-Cox,et al.  Clinical pathways for patients with newly diagnosed hepatitis C – What actually happens , 2006, Journal of viral hepatitis.

[15]  P. Villeneuve,et al.  Reduction in injection-related HIV risk after 6 months in a low-threshold methadone treatment program. , 2007, AIDS education and prevention : official publication of the International Society for AIDS Education.

[16]  B. Conway,et al.  Hepatitis C virus reinfection in injection drug users , 2006, Hepatology.

[17]  T. Nichols,et al.  Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial , 2008, Journal of viral hepatitis.

[18]  M. Manns,et al.  Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C , 2000, Nature Medicine.

[19]  W. van den Brink,et al.  Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials , 2005, BMJ : British Medical Journal.

[20]  J. Lefrère,et al.  Complete or partial seroreversion in immunocompetent individuals after self‐limited HCV infection: consequences for transfusion , 2004, Transfusion.

[21]  M. Youle,et al.  Assessing the cost‐effectiveness of HAART for adults with HIV in England , 2001, HIV medicine.

[22]  S M Gore,et al.  Progression of HIV: follow‐up of Edinburgh injecting drug users with narrow seroconversion intervals in 1983–1985 , 1996, AIDS.

[23]  Jonathan AC Sterne,et al.  Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study , 2005, The Lancet.

[24]  J. Kaldor,et al.  Effectiveness of needle-exchange programmes for prevention of HIV infection , 1997, The Lancet.

[25]  V. Hope,et al.  Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004 , 2007, Journal of viral hepatitis.

[26]  M. Farrell,et al.  Drug-related mortality and fatal overdose risk: Pilot cohort study of heroin users recruited from specialist drug treatment sites in London , 2003, Journal of Urban Health.

[27]  Federica Vigna-Taglianti,et al.  Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. , 2007, Addiction.

[28]  Terry L. Schell,et al.  Examination of the association between syringe exchange program (SEP) dispensation policy and SEP client-level syringe coverage among injection drug users. , 2007, Addiction.

[29]  J. Lefrère,et al.  Full or partial seroreversion in patients infected by hepatitis C virus. , 1997, The Journal of infectious diseases.

[30]  T. Déirdre Hollingsworth,et al.  Variation in HIV-1 set-point viral load: Epidemiological analysis and an evolutionary hypothesis , 2007, Proceedings of the National Academy of Sciences.

[31]  R. Brettle,et al.  Pre-AIDS deaths in HIV infection related to intravenous drug use. , 1997, QJM : monthly journal of the Association of Physicians.

[32]  K. Agarwal,et al.  Managing chronic hepatitis C acquired through intravenous drug use. , 2001, QJM : monthly journal of the Association of Physicians.

[33]  B. Conway,et al.  Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. , 2007, The International journal on drug policy.

[34]  R. Bluthenthal,et al.  Higher syringe coverage is associated with lower odds of HIV risk and does not increase unsafe syringe disposal among syringe exchange program clients. , 2007, Drug and alcohol dependence.

[35]  M. Hellard,et al.  Consecutive infections and clearances of different hepatitis C virus genotypes in an injecting drug user. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[36]  P Vickerman,et al.  Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study. , 2007, International journal of epidemiology.

[37]  R. Rapp,et al.  Case management for persons with substance use disorders. , 2014, The Cochrane database of systematic reviews.

[38]  F. Faggiano,et al.  Methadone maintenance at different dosages for opiod dependence (Cochrane Review) , 2003 .

[39]  D. Vlahov,et al.  Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  R. Baggaley,et al.  Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis , 2006, AIDS.

[41]  J. Castilla,et al.  Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain. , 2006, AIDS research and human retroviruses.

[42]  P. Royle,et al.  Screening for Hepatitis C in injecting drug users: a cost utility analysis. , 2004, Journal of public health.

[43]  M. Brandeau,et al.  The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. , 2001, Addiction.

[44]  N. Waugh,et al.  Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C : a systematic review and economic evaluation , 2007 .

[45]  Neil M Ferguson,et al.  Modelling the Impact of Antiretroviral Use in Resource-Poor Settings , 2006, PLoS medicine.

[46]  M. Singer,et al.  Effects of increasing syringe availability on syringe-exchange use and HIV risk: Connecticut, 1990–2001 , 2002, Journal of Urban Health.

[47]  R. Bluthenthal,et al.  Injection Risk Behaviors Among Clients of Syringe Exchange Programs With Different Syringe Dispensation Policies , 2004, Journal of acquired immune deficiency syndromes.

[48]  C. Watts,et al.  Could the CARE-SHAKTI intervention for injecting drug users be maintaining the low HIV prevalence in Dhaka, Bangladesh? , 2007, Addiction.

[49]  C. Watts,et al.  The Cost-Effectiveness of Expanding Harm Reduction Activities for Injecting Drug Users in Odessa, Ukraine , 2006, Sexually transmitted diseases.

[50]  H. Thomas,et al.  Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial , 2005, Journal of viral hepatitis.

[51]  J. Havens,et al.  Facilitating entry into drug treatment among injection drug users referred from a needle exchange program: Results from a community-based behavioral intervention trial. , 2006, Drug and alcohol dependence.

[52]  O. Laeyendecker,et al.  Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. , 2005, The Journal of infectious diseases.

[53]  S. Giampaoli,et al.  Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population , 2002, Gut.

[54]  William C Miller,et al.  Frequent detection of acute primary HIV infection in men in Malawi , 2004, AIDS.

[55]  D. Gibson,et al.  Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. , 2001, AIDS.

[56]  E H Kaplan,et al.  A circulation theory of needle exchange. , 1994, AIDS.

[57]  E H Kaplan,et al.  A model-based estimate of HIV infectivity via needle sharing. , 1992, Journal of acquired immune deficiency syndromes.

[58]  R. Coutinho,et al.  Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users , 2007, Addiction.

[59]  T. Roberts,et al.  Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation. , 2007, Health technology assessment.

[60]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[61]  M. Brugal,et al.  Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. , 2005, Addiction.

[62]  D. D. Des Jarlais,et al.  Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990–2001 , 2005, AIDS.

[63]  T. Quinn,et al.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.

[64]  R. Brettle,et al.  Do HIV Disease Progression and HAART Response Vary among Injecting Drug Users in Europe? , 2005, European Journal of Epidemiology.

[65]  A. Caliendo,et al.  Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA , 2000, AIDS.

[66]  R. Anderson,et al.  Balancing sexual partnerships in an age and activity stratified model of HIV transmission in heterosexual populations. , 1994, IMA journal of mathematics applied in medicine and biology.

[67]  A. Larghi,et al.  Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies , 2002, Hepatology.